相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Bryan D. Choi et al.
NATURE BIOTECHNOLOGY (2019)
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies
Bryan D. Choi et al.
CLINICAL CANCER RESEARCH (2019)
Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection
Julian J. Albers et al.
LIFE SCIENCE ALLIANCE (2019)
Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons
Bryan D. Choi et al.
NEUROSURGICAL FOCUS (2018)
Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
Carter M. Suryadevara et al.
ONCOIMMUNOLOGY (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 thorn Breast Cancer Metastasis to the Brain
Saul J. Priceman et al.
CLINICAL CANCER RESEARCH (2018)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer
Shu Su et al.
ONCOIMMUNOLOGY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE 143
D. A. Reardona et al.
NEURO-ONCOLOGY (2017)
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer
Nathan Singh et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Shu Su et al.
SCIENTIFIC REPORTS (2016)
TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer
B. Berdien et al.
GENE THERAPY (2014)
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma
Bryan D. Choi et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2014)
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
Hiroki Torikai et al.
BLOOD (2013)
Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice
Luis A. Sanchez-Perez et al.
PLOS ONE (2013)
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Elena Provasi et al.
NATURE MEDICINE (2012)
Programmed Death 1 Regulates Development of Central Memory CD8 T Cells after Acute Viral Infection
S. Rameeza Allie et al.
JOURNAL OF IMMUNOLOGY (2011)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
分享论文
